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Abstract
Limitations associated with demineralised bone matrix and 
other grafting materials have motivated the development 
of alternative strategies to enhance the repair of large 
bone defects. The growth plate (GP) of developing limbs 
contain a plethora of growth factors and matrix cues 
which contribute to long bone growth, suggesting that 
biomaterials derived from its extracellular matrix (ECM) 
may be uniquely suited to promoting bone regeneration. 
The goal of this study was to generate porous scaffolds 
from decellularised GP ECM and to evaluate their ability 
to enhance host mediated bone regeneration following 
their implantation into critically-sized rat cranial defects. 
The scaffolds were first assessed by culturing with 
primary human macrophages, which demonstrated that 
decellularisation resulted in reduced IL-1β and IL-8 
production. In vitro, GP derived scaffolds were found 
capable of supporting osteogenesis of mesenchymal stem 
cells via either an intramembranous or an endochondral 
pathway, demonstrating the intrinsic osteoinductivity of the 
biomaterial. Furthermore, upon implantation into cranial 
defects, GP derived scaffolds were observed to accelerate 
vessel in-growth, mineralisation and de novo bone 
formation. These results support the use of decellularised 
GP ECM as a scaffold for large bone defect regeneration.
Keywords: Growth plate, Extracellular matrix, Scaffold, 
Large bone defect regeneration, Scaffold immune response.
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Introduction
The repair of large bone defects still presents a significant 
clinical challenge, with the use of autografting material 
remaining the gold standard treatment despite the 
drawbacks associated with this approach (Dimitriou et 
al., 2011). Biological scaffolds derived from animal and 
human extracellular matrix (ECM), which are composed of 
instructive structural and functional molecules to facilitate 
tissue regeneration, have been successfully used clinically 
to repair numerous different tissues and organs (Benders 
et al., 2013). Demineralised bone matrix is commonly 
used in bone regeneration (Gruskin et al., 2012; Solheim, 
1998), although concerns remain as to its osteoinductivity 
(Aghdasi et al., 2013; An et al., 1995; Tilkeridis et al., 
2014). Long bones form by the coordinated process of 
endochondral ossification, with the postnatal growth and 
development of our limbs driven by the growth plates 
(also called the epiphyseal plates). The growth plate (GP) 
is known to contain members of the transforming growth 
factor (TGF)-β family, including bone morphogenetic 
protein (BMP), as well as vascular endothelial growth 
factor (VEGF) and Indian hedgehog (Ihh), which are 
known to be strongly osteoinductive (Alini et al., 1992; 
Anderson et al., 2000; Carlevaro et al., 2000; Gerber et al., 
1999; Kronenberg, 2003; Nilsson et al., 2007; Qiu et al., 
2015; Wang et al., 2004). Indeed, powdered demineralised 
GP has been shown to be osteoinductive in vivo, supporting 
the development of a bone ossicle following ectopic 
implantation into rats (Bigham et al., 2011). Clearly, such 
ECM derived biomaterials have tremendous potential 
for bone regeneration; however, realising this potential 
requires processing them into biological scaffolds capable 
of facilitating vascularisation and host osteo-progenitor 
mediated bone formation.
 The ideal scaffold for bone regeneration is biocompatible, 
allows for cell infiltration and provides instructive cues 
to infiltrating cells, preferably to induce an osteogenic 
response. Porous scaffolds produced using collagen and 
hydroxyapatite, the two main constituents of bone, have 
been shown to encourage osteogenesis of MSCs in vitro 
and can support bone regeneration in vivo (Calabrese et 
al., 2016; Chen et al., 2015; Cunniffe et al., 2010; Cunniffe 
and O’Brien, 2011; David et al., 2015; Gleeson et al., 
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2010; Prosecka et al., 2015; Villa et al., 2015). Ideally 
scaffolds have an open interconnected pore structure, 
with pore sizes in the range of 85-325 µm best supporting 
osteogenesis (Karageorgiou and Kaplan, 2005; Murphy 
et al., 2010; O’Brien et al., 2007). The osteoinductivity 
of these scaffolds can be improved by the incorporation 
of gene and growth factors such as BMP-2 and VEGF 
(Quinlan et al., 2015a; Quinlan et al., 2015b; Samorezov 
and Alsberg, 2015), although it remains uncertain as to 
what is the ideal combination of matrix components and 
growth factors to safely induce osteogenesis without the 
need for excessive levels of growth factors.
 Rather than building a bone mimetic scaffold from the 
bottom-up using collagen and mineral components found 
in bone, and then systematically incorporating growth 
factors into such a construct, the goal of this study was 
instead to produce a porous osteoinductive scaffold from 
decellularised growth plate, the precursor matrix of long 
bones. Native and in vitro cell culture derived ECMs are 
commonly used to produce scaffolds for tissue engineering 
(Almeida et al., 2014; Cunniffe et al., 2015; Jin et al., 
2007; Kheir et al., 2011; Kim et al., 2015; Lau et al., 
2012; Lu et al., 2011; Pati et al., 2015; Pattabhi et al., 
2014; Sutherland et al., 2015); however, the ideal matrix 
to facilitate bone regeneration has yet to be established. As 
previously stated, the GP matrix contains many important 
growth factors for inducing bone growth which render it 
as an attractive option for generating an osteoinductive 
ECM derived scaffold. The hypothesis of this study is that 
a decellularised GP ECM derived scaffold will support 
vascularisation and accelerated bone formation following 
implantation into critically-sized defects. The first objective 
of the study was to decellularise GP ECM and to use this 
biomaterial to produce a porous scaffold. We next evaluated 
the osteoinductivity of this scaffold in vitro by assessing 
its capacity to promote osteogenesis of MSCs via either an 
intramembranous or an endochondral pathway. The final 
phase of the study assessed the capacity of these scaffolds 
to support healing of critically-sized rat cranial defects.
Materials and Methods
Decellularisation and scaffold fabrication
Growth plate (GP) tissue was harvested from the femur and 
tibia of porcine hind limbs (3-4 months old) shortly after 
sacrifice. The GP region was reached by sawing the bone 
through the long axis, and breaking the bone open along the 
softer GP region, allowing the GP tissue to be scraped out in 
small pieces using a scalpel (~1 mm3). These small pieces 
were then minced in distilled H20 using a homogeniser 
(IKAT10, IKA® Works Inc., NC, USA) to create an ECM 
slurry. The effect of decellularisation was evaluated, 
comparing native GP (no additional treatment prior to 
freeze-drying), to a detergent-based technique using 0.1 % 
sodium dodecyl sulphate (SDS; Sigma-Aldrich); following 
comparisons with other detergents commonly used for 
decellularisation (Cheng et al., 2014; Gilbert et al., 2006; 
Luo et al., 2016; Luo et al., 2015), results not shown. 
Decellularised GP slurry underwent two freeze-thaw 
cycles in a hypotonic buffer (10 mM Trizma hydrochloride 
and 5 mM ethylenediaminetetraacetic acid (EDTA) at 
pH 7.4), washed in saline (PBS), and treated for 1 h at 
room temperature in 0.1 % SDS. Following subsequent 
PBS washes, the slurry was placed in a DNase/RNase 
solution (5 mM MgCl2, 10 U/mL of DNase, and 10 U/
mL of RNase) and incubated for 1 h at 37 °C. Following 
this initial evaluation, all succeeding GP scaffolds used in 
the in vitro and in vivo studies were decellularised using 
this method.
 The homogenised tissues (native GP, or decellularised 
GP) were centrifuged and the supernatant was removed. 
The remaining material was re-suspended in distilled 
H2O at a concentration of 500 mg/mL. The slurry was 
transferred to custom-made specific polydimethylsiloxane 
(PDMS) cylindrical moulds (resulting in constructs of 
5 mm × 3 mm for in vitro, and 7 mm × 2 mm for in vivo 
studies) and freeze-dried (Triad, Labconco, KC, USA) to 
produce porous scaffolds. Briefly, the slurry temperature 
was reduced to −30 °C (1 °C/min) and maintained for 
1 h to allow for ice-crystal nucleation and growth. The 
temperature was then increased to −10 °C (1 °C/min), 
followed by a hold of 24 h to allow for sublimation of the 
liquid phase, and then finally increased to room temperature 
(0.5 °C/min). Scaffolds then underwent dehydrothermal 
crosslinking (DHT) as previously described in the 
literature (Haugh et al., 2009). The DHT process was 
performed in a vacuum oven (VD23, Binder, Germany), 
at 105 °C, at 0.5 mbar for 24 h. This was then followed 
by a chemical cross-linking treatment using 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDAC; 6 mM for 
2 h with two washes in sterile phosphate buffered saline 
2 × 1 h). Scaffolds were either seeded with cells for the in 
vitro analysis, or implanted cell-free for the in vivo study.
Scanning Electron Microscopy (SEM)
Scaffolds were imaged using SEM to visualise the internal 
porous structure of the freeze-dried constructs. Imaging 
was carried out following DHT treatment by fixing 
constructs to an adhesive carbon stub, sputter coating 
with gold, and imaging using a lens detector with a 5 kV 
acceleration voltage at calibrated magnifications (Tescan 
Mira XMU, Tescan USA Inc.).
Biochemical analysis of DNA, sGAG and calcium
Scaffolds formed from native GP, and decellularised GP 
matrix were evaluated (n = 3) for their residual DNA, 
sulphated glycosaminoglycan (sGAG) and calcium content 
post fabrication. Scaffolds were digested with papain 
(125 μg mL−1) in 0.1 M sodium acetate, 5 mM L-cysteine-
HCl, 0.05 M EDTA, pH 6.0 (all from Sigma-Aldrich) at 
60 °C and 10 rpm for 18 h. DNA content was quantified 
using the Hoechst Bisbenzimide 33258 dye assay, with a 
calf thymus DNA standard (Sigma-Aldrich). The amount 
of sGAG was quantified using the dimethyl methylene 
blue (DMMB) dye-binding assay (Blyscan, Biocolor 
Ltd., Northern Ireland), with a chondroitin sulphate 
standard and both were normalised by scaffold weight. 
To quantify calcium deposition, scaffolds were chemically 
digested in 1 M HCL at 60 °C under rotation for 18 h, 
and an O-cresolphthalein complexone (oCPC; Sentinel 
Diagnostics, Italy) assay was performed. Cell-seeded 
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constructs were also analysed (n = 3) for their sGAG and 
calcium content following 28 d in culture using the same 
protocols.
Innate immune response analysis
Cytokine production measured by ELISA
In order to characterise the immune cell response to 
the native and decellularised GP scaffolds, primary 
human macrophages were seeded onto the scaffolds and 
analysed. Peripheral blood mononuclear cells (PBMC) 
were isolated by means of density gradient centrifugation 
from leukocyte-enriched buffy coats from anonymous 
healthy donors, obtained with permission from the Irish 
Blood Transfusion Board, St. James’s Hospital, Dublin. 
CD14+ myeloid cells were purified from PBMC by 
means of positive selection using anti-CD14 magnetic 
beads according to the manufacturer’s protocol (Miltenyi 
Biotech, Germany) (Corr et al., 2016; Safi et al., 2016). 
Cells were shown to be >90 % pure as determined by flow 
cytometry. CD14⁺ monocytes were differentiated into 
macrophages for 6 d in the presence and absence growth 
plate scaffolds using M-CSF (50 ng/mL). As a positive 
control, macrophages were also stimulated with 100 ng/mL 
LPS for 24 h. Cytokine production was quantified in cell 
supernatants by ELISA (IL-1β and TNF, R&D Systems; 
IL-12 and IL-8, eBiosciences).
Real-time PCR 
Primary human macrophages (7.5 × 10^⁵ cells/mL) were 
polarised to an M1 phenotype with IFNγ (10 ng/mL) for 
24 h in the presence and absence of native and decellularised 
GP scaffolds. RNA was extracted from cells using the High 
Pure RNA Isolation Kit (Roche, Basel, Switzerland) and 
assessed for concentration and purity using the NanoDrop 
2000c UV-Vis spectrophotometer. RNA was equalised 
and reverse transcribed using the Applied Biosystems 
High-Capacity cDNA reverse transcription kit. Real-time 
quantitative PCR was carried out on triplicate cDNA 
samples with the use of the CFX96 Touch Real-Time 
PCR Detection System (Bio-Rad Laboratories, Hercules, 
California). Real-time PCR for the detection of CCL19 
and CXCL11 mRNA was performed using the TaqMan 
fast universal PCR Master Mix (Applied Biosystems) and 
predesigned TaqMan gene expression primers. Amounts 
of mRNA were normalised relative to the housekeeping 
gene Ribosomal Protein 18S.
In vitro analysis with bone marrow derived MSCs
Bone marrow derived mesenchymal stem cells (BMSCs) 
were harvested from the femora of porcine hind legs, and 
expanded using standard culture conditions. BMSCs were 
expanded to passage 2 and seeded onto the GP scaffold at a 
density of 0.5 × 10^6 cells per scaffold. Cells were allowed 
to attach to the scaffolds for 1 h in the incubator at 37 °C 
before culturing in either chondrogenic or osteogenic 
medium for 28 d in normoxic conditions (20 % O2 and 
5 % CO2). The constructs were cultured in 5 mL of either 
(i) chondrogenic media: Dulbecco’s modified Eagle’s 
medium (DMEM) + GlutaMAX™ (Gibco), 1 mM sodium 
pyruvate, 350 μM L-proline, 1.5 mg/mL bovine serum 
albumin (BSA), 1 nM dexamethasone, 300 μM ascorbic 
acid, 17 μM linolenic acid, 10 ng/mL transforming growth 
factor β3 (TGF-β3, ProSpec-Tany, Israel), 1X insulin-
transferrin-selenium; or (ii) osteogenic media: DMEM + 
GlutaMAX™, 10 % foetal bovine serum (Gibco), 10 mM 
β-glycerophosphate, 1 nM dexamethasone, 0.09 mM 
ascorbic acid. Both media were supplemented with 
100 units/mL penicillin, 100 units/mL streptomycin and 
0.25 μg/mL amphotericin B.
Histology and immunohistochemistry
Samples were fixed in 4 % paraformaldehyde (PFA) 
overnight, dehydrated in a graded series of ethanol and 
xylenes, and embedded in paraffin wax. In vivo samples 
were decalcified following fixation using an EDTA 
treatment (15 % EDTA at pH 7.4) to remove the mineral 
component prior to embedding. Sections of 8 μm were 
obtained with a microtome (Leica RM2125RT) and 
affixed to microscope slides. Prior to staining, sections 
were dewaxed and rehydrated in 100-70 % ethanol 
followed by distilled water. The deposition of sGAG, 
collagen and calcium over 28 d in vitro was evaluated 
using 1 % alcian blue in 0.1 M HCl, picrosirius red, and 
1 % alizarin red solutions respectively. Post-implantation 
samples were evaluated for cellular infiltration and bone 
matrix deposition with haematoxylin and eosin (H&E) and 
deposition of sGAG with safranin-O (all Sigma-Aldrich). 
Evaluation of vessel number and bone area quantification 
were performed on histological samples stained for H&E, 
by counting vessels visible across an entire section, under a 
microscope at 20×, and using Adobe Photoshop and Image 
J to determine bone area.
 Collagen type II and type X deposition was evaluated 
using a standard immunohistochemical technique (Sheehy 
et al., 2015). Briefly, sections (n = 4 sections per group) 
were treated with hydrogen peroxidase (Sigma-Aldrich), 
followed by enzymatic treatment with pronase (0.5 mg/mL, 
Merck Millipore) in a humidified environment for 5 min at 
37 °C to enhance the permeability of the ECM. Sections 
were incubated with goat serum to block non-specific sites 
and mouse monoclonal IgG anti-collagen type II (ab3092, 
1:100) and mouse monoclonal IgM anti-collagen type 
X (ab49945, 1:200) primary antibodies (Abcam) were 
applied overnight at 4 °C. Next, the secondary antibody 
(Collagen type II; goat anti-mouse IgG, 1:200, B7151 
Sigma-Aldrich and Collagen type X; goat anti-mouse 
IgM, 1:200, ab49760 Abcam, UK) was added for 1 h, 
followed by incubation with ABC reagent (Vectastain 
PK-400, Vector Labs) for 45 min. Finally, sections were 
developed with DAB peroxidase (Vector Labs) for 5 min. 
Positive and negative controls were included in the 
immunohistochemistry staining protocol for each batch.
Cranial defect implantation
A cranial defect was created in adult male Fischer rats 
following an established procedure (Lyons et al., 2010), 
with n = 4 animals per group at two time points of 4 and 
8 weeks. Anaesthesia was induced with an intraperitoneal 
injection of xylazine hydrochloride (10 mg/kg) and 
ketamine hydrochloride (75 mg/kg), and maintained with 
inhalational isoflurane and oxygen (0.5-2 % isoflurane). 
A 7 mm circular transosseous defect was created on the 
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left side of the rat parietal calvarium using a grinding 
burr and the GP scaffold (decellularised but not EDTA-
treated) was immediately implanted into the defect or left 
untreated for the empty defect (ED) groups before closing 
of the wound with sutures. Atipamezole hydrochloride was 
given to reverse sedation. Pain relief was administered via 
carprofen and buprenorphine subcutaneous injections over 
the following 2 d. On dates of scheduled explant retrieval, 
rats were sacrificed by CO2 asphyxiation and cervical 
dislocation, and calvaria were harvested for evaluation. 
Ethical approval was given by the Research Ethics 
Committee of the Royal College of Surgeons in Ireland and 
an animal licence was granted by the Department of Health 
and Children (Ref. B100/4490) prior to initiation of study.
Micro-computed tomography
Micro-computed tomography (µCT) scans were carried out 
on the explants from the cranial study in order to visualise 
and quantify mineral content and distribution. A Scanco 
Medical 40 μCT system (Scanco Medical, Bassersdorf, 
Switzerland) was used for evaluation with a 70 kVp X-ray 
source at 114 μA. Four constructs were analysed per 
experimental group and per time point. Reconstructed 3D 
images were generated from the scans and used to visualise 
mineral distribution throughout the implanted scaffold or 
control group. Quantification was performed by setting a 
threshold of 165, corresponding to 339 mg HA/cm^3, and 
recording the bone volume (BV) within the defect per total 
volume (BV/TV), using a consistent total volume (5 mm 
diameter and 50 slices in the Z direction, voxel size 20 μm) 
from sample to sample which eliminated original bone 
from the calculations (Cunniffe et al., 2016).
Statistical Analysis
All statistical analyses were carried out using GraphPad. 
The results are reported as means ± standard deviation. 
Groups were analysed by a general linear model for 
analysis of variance with groups of factors. Tukey’s test or 
student t-tests were used to compare groups. Significance 
was accepted at a level of p < 0.05.
Fig. 1. a). Scanning electron microscopy (SEM) images of the GP scaffold indicating the open interconnected porosity 
achieved post-lyophilisation. b). Biochemical analysis of residual DNA, sGAG and calcium following the 0.1 % SDS 
decellularisation treatment, compared to the native GP scaffold. (a) p<0.05 (unpaired t-test).
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Results
Porous scaffolds can be fabricated using porcine 
Growth Plate (GP) ECM
Scaffolds were generated by lyophilisation of slurries of GP 
matrix, resulting in constructs with an open, interconnected 
porosity, with a mean pore size of 126 ± 52 µm, suitable for 
cellular infiltration and migration (Fig. 1a). Biochemical 
analysis of decellularised GP (0.1 % SDS treatment) 
indicated that sGAG and calcium could be retained within 
the matrix, with no significant reduction in the levels of 
these ECM components compared to the untreated native 
GP control (Fig. 1b). A significant reduction in DNA 
content was observed following decellularisation.
 The scaffolds were next assessed by culturing primary 
human macrophages in the presence of native and 
decellularised (0.1 % SDS) GP. LPS, a potent driver of 
pro-inflammatory cytokine production, was included as a 
positive control. No increase in IL-12 or TNF production 
was detected with either material (Fig. 2a,b). Robust 
IL-8 production was observed in the supernatants of 
macrophages cultured with native GP; however this was 
significantly lower with decellularised GP (Fig. 2c). Native 
GP produced comparable levels of IL-1β to LPS and again 
this was reduced in the presence of the decellularised 
material (Fig. 2d).
 The effect of the scaffolds on M1-associated macrophage 
polarisation was next assessed. In this case, macrophages 
were cultured in the presence of native and decellularised 
GP prior to treatment with the M1 polarising cytokine, 
IFNγ. As expected, IFNγ increased the expression of the 
M1 associated genes, CCL19 and CXCL11, and this was 
not altered by the presence of the scaffolds (Fig. 2e,f).
MSC seeded GP ECM scaffolds mineralise in either 
chondrogenic or osteogenic culture conditions
Independent of the culture conditions, bone marrow derived 
MSCs cultured on GP scaffolds were observed to deposit 
a densely calcified matrix over 28 d in vitro (Fig. 3a,b). 
The constructs cultured in chondrogenic conditions stained 
Fig. 2. a-d). The effect of growth 
plate scaffolds on cytokine 
production and macrophage 
phenotype. Human monocytes 
w e r e  d i f f e r e n t i a t e d  i n t o 
macrophages in the presence of 
native and 0.1 % SDS treated 
growth plate for 6 d. As a positive 
control,  macrophages were 
treated with 100 ng/mL LPS 
for 24 h. Cytokine production 
was quantified by ELISA. e,f). 
Macrophages were polarised to an 
M1 phenotype with IFNγ (10 ng/
mL) for 24 h in the presence and 
absence of scaffolds. The mRNA 
expression was quantified by real-
time PCR. (b) p < 0.001 and (a) 
p < 0.05.
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Fig. 3. a). Histological analysis of scaffolds at day 0, and MSC-seeded constructs after 28 d in either chondrogenic 
or osteogenic conditions. Deposition of sGAG, collagen, collagen type II and X and calcium is observed, particularly 
in the construct cultured in chondrogenic medium. b). Biochemical analysis of the calcium deposited by MSCs over 
the culture period (a) p < 0.05.
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more intensely for sGAG, collagen type II and type X after 
28 d in culture compared to MSC-laden scaffolds cultured 
in osteogenic conditions, suggesting the development of a 
hypertrophic cartilage matrix that was calcifying in vitro. 
Quantification of the mineral deposition demonstrated 
that similar levels of calcium had accumulated within 
the scaffolds maintained in chondrogenic and osteogenic 
culture conditions (Fig. 3b).
 In an attempt to elucidate the relative role of the unique 
collagenous matrix of the GP over other non-collagenous 
components in driving this cell-mediated mineral 
deposition, day 0 GP scaffolds were treated with EDTA 
in order to completely remove the mineral content prior 
to cell-seeding, leaving behind only a collagenous matrix 
(Day 0 calcium levels pre-decalcifying were 7.8 ± 0.3 µg/
mg scaffold, and these values were subtracted from the 
day 28 results). Demineralised GP scaffolds were capable 
of supporting similar levels of sGAG accumulation over 
the 28 d in chondrogenic culture conditions; however, 
the ability of these scaffolds to induce mineralisation was 
significantly hampered (Fig. 4a-d), with no evidence of 
cell-mediated mineralisation detected in these constructs.
GP ECM derived scaffolds can accelerate endogenous 
bone regeneration in a critically-sized cranial defect
Having demonstrated the osteogenicity of GP ECM 
scaffolds in vitro, we next implanted them cell-free 
into 7 mm cranial defects, with healing analysed 4 and 
8 weeks after implantation and compared to untreated 
controls. Reconstructed 3D μCT images demonstrated 
the widespread deposition of bone at both time points 
post-implant (Fig. 5a,b). Upon closer inspection, small 
nodules of mineral were found homogeneously distributed 
throughout the defect. Quantification of the bone 
volume per total defect volume (BV/TV) demonstrated 
significantly greater levels of mineralised tissue at both 4 
and 8 weeks vs. empty groups (Fig. 5c).
 Histological analysis (H&E) of the harvested samples 
demonstrated bone formation within the GP scaffold treated 
groups at 4 and 8 weeks, compared to predominantly 
fibrous tissue bridging the defect in the untreated group 
(Fig. 6a). Positive safranin-O staining for sGAG deposition 
was observed within the scaffold treated groups at 4 weeks, 
and to a lesser degree at 8 weeks (Fig. 6b). This appeared to 
be staining of the residual GP cartilage within the scaffold, 
Fig. 4. a,b). Histological and biochemical analysis of sGAG deposition by MSCs at day 28 in chondrogenic culture 
conditions, seeded on a GP scaffold and a demineralised GP scaffold. c,d). Histological and biochemical analysis of 
calcium deposition occurring over the culture period on the GP and demineralised GP scaffolds.
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and not evidence of bone forming via endochondral 
ossification. In addition, histomorphometric analysis of 
H&E stained slices allowed for determination of bone 
area within the defect, revealing a significant difference 
between the GP scaffold group and the empty control 
(Fig. 6c). Quantification of vessel number also indicated 
a significantly higher number of vessels were observed 
within the GP treated groups at both 4 and 8 weeks (Fig. 
6d).
Discussion
The overall goal of this study was to develop porous 
scaffolds from GP ECM and to evaluate its potential as a 
biomaterial for promoting bone regeneration. The innate 
immune response of the scaffolds was assessed by culturing 
with primary human macrophages, which demonstrated 
that decellularisation resulted in reduced IL-1β and IL-8 
production. These decellularised scaffolds were able to 
support osteogenesis of MSCs in vitro in both osteogenic 
Fig. 5. a,b). Reconstructed µCT images indicate a distribution of mineral throughout GP scaffold treated defects, 
in comparison to the empty controls. c). A graph of the bone volume to total volume at both 4 and 8 weeks for GP 
treated and untreated (ED) groups. (a) p < 0.05.
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and chondrogenic culture conditions, and their acellular 
implantation into a critically-sized defect accelerated 
vascularisation and endogenous bone formation and repair. 
Taken together, these findings indicate the potential of 
this novel ECM derived biomaterial for large bone defect 
healing.
 Calcified tissue was observed in MSC-seeded GP 
scaffolds cultured in both chondrogenic and osteogenic 
conditions after 28 d in vitro. The presence of collagen 
type II, type X and sGAG indicate that the mineralisation 
achieved in chondrogenic media was occurring via 
an endochondral route compared to that arising in the 
constructs cultured in osteogenic media. GP scaffolds 
seeded with MSCs and cultured in standard expansion 
medium (containing serum) also extensively mineralised 
(data not shown). Interestingly, however, when the GP 
scaffold was further treated with a decalcifying agent 
prior to cell seeding, the matrix failed to induce any 
cell-mediated mineral deposition when maintained in 
chondrogenic culture conditions. This would suggest 
that the relatively low mineral component within the 
GP is a dominant osteoinductive component rather than 
the collagenous matrix itself, although at this stage we 
cannot rule out a potential role for other non-collagenous 
proteins and growth factors that may be removed by 
EDTA treatment. Further proteomic analysis of the GP 
post scaffold fabrication is required to fully identify the 
key matrix components influencing cell differentiation and 
bone formation.
 Successful integration of ECM scaffolds is dependent 
on appropriate host immune responses; therefore, 
preliminary assays were carried out to examine their 
effect on primary human macrophages. The production 
of key pro-inflammatory cytokines and chemokines was 
assessed and, as demonstrated, the production of IL-12, 
which links innate and adaptive immune responses was 
minimal. This was also the case for the highly inflammatory 
cytokine, TNFα. Interestingly, native GP induced high 
Fig. 6. a-b). Histological analysis of GP scaffold treated and empty cranial defects at 4 and 8 weeks post implantation, 
indicating de novo bone formation, sGAG, and collagen/connective tissue deposition. Higher magnification images 
are presented for the 8 week images. c,d). Quantification of the bone area per defect and vessel number within the 
defect at both time points (ED; empty defect, GP; growth plate). (a) p < 0.05.
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levels of the chemokine, IL-8, which is a key driver of 
neutrophil chemotaxis and has the potential to exacerbate 
inflammatory responses. Importantly, decellularisation 
of GP with 0.1 % SDS reduced IL-8 production by 
approximately 50 %. It will be interesting to determine the 
precise role played by this chemokine in host interactions 
with ECM scaffolds. Of note, it has been shown that IL-8 
can promote osteoclastogenesis (Kopesky et al., 2014); 
therefore, a certain level of this protein may actually be 
beneficial for optimal remodelling. We also assessed the 
effect of the scaffolds on macrophage phenotype given 
that they are likely to be implanted into an inflammatory 
micro-environment. Encouragingly, the scaffolds did not 
enhance the expression of genes that are associated with 
an inflammatory M1 macrophage phenotype. Furthermore, 
treatment with SDS appeared to reduce the expression of 
some M1 associated markers.
 The only evidence of native GP material being used to 
treat bone defects, to the best of our knowledge, was in a 
series of recent studies where GP tissue was demineralised 
in a manner similar to bone matrix (DBM), and the resultant 
powder used to fill bone defects. This demineralised GP 
powder demonstrated an ability to achieve mineralisation 
in vivo, both ectopically in rat muscle, and orthopically in 
a rat spine defect and a rabbit radial defect study (Bigham-
Sadegh et al., 2014; Bigham et al., 2011; Shadkhast 
and Bighamsadegh, 2011). These studies pointed to 
the presence of potent growth factors from the TGF-β 
super-family within the GP matrix as potentially leading 
to the observed bone deposition. In a similar study, the 
authors reported enhanced bone formation when the 
demineralised GP powder was supplemented with synthetic 
hydroxyapatite (Bigham-Sadegh et al., 2015). This may be 
related to the in vitro results observed in this study, where 
EDTA treatment to remove the calcium within the GP 
scaffolds was found to dramatically reduce their capacity 
to support an endochondral phenotype.
 Analysis of defects treated with an acellular GP scaffold 
illustrated that endogenous cells were capable of infiltrating 
throughout the porous scaffold, facilitating mineralisation 
and de novo bone formation by 4 weeks. Quantification 
of the bone volume also indicates the beneficial effect of 
implanting the GP scaffold, with enhanced levels observed 
by 4 weeks. This distribution throughout the implanted 
material is highly favourable, as constructs can often 
become surrounded by new tissue, with mineralisation 
observed predominantly on the periphery of the implanted 
material, leading to core necrosis and implant failure 
(Lyons et al., 2010). The high porosity of the scaffold 
clearly facilitated excellent cell infiltration and vessel in-
growth, which ultimately contributed to the enhanced bone 
formation observed throughout the defect. The GP matrix is 
known to contain potent angiogenic growth factors which 
may have played a role in enhancing angiogenesis within 
the scaffold treated defects (Qiu et al., 2015). Comparable 
studies in the literature, using collagen based scaffolds to 
treat rat cranial defects, have demonstrated the need to 
incorporate exogenous factors such as BMP-2 (Quinlan 
et al., 2015b) and/or VEGF (Curtin et al., 2014) to induce 
robust bone healing. The fact that GP derived scaffolds 
can promote healing without the need for the additional 
delivery of exogenous factors such as BMP-2, which can 
have potent off-target effects (Benglis et al., 2008; Cahill 
et al., 2009), points to their potential use as a safe, low-
cost and effective biomaterial for the repair or large bone 
defects. It should be noted, however, that our studies have 
been performed in relatively low-load bearing defects, and 
follow-up studies are required to assess their efficacy in 
more mechanically challenging locations.
 While positive staining for cartilage specific matrix 
components was observed in scaffold treated defects, this 
was predominately staining of residual scaffold material 
and not necessarily evidence of endochondral bone healing, 
although we cannot completely rule out the possibility of 
this occurring. Cranial bones form via intramembranous 
ossification during embryonic development, although 
previous studies have also shown that healing in this 
region can occur along the endochondral route (Jukes et 
al., 2008; Lin et al., 2013). Future studies are required to 
further quantify the exact temporal patterns of repair within 
defects treated with GP ECM derived scaffolds.
 Analysing the quality of the de novo tissue forming 
in more detail showed that newly deposited bone was 
replacing the GP ECM scaffold, with remodelling of the 
scaffold evident between week 4 and 8, as demonstrated by 
a reduction in residual scaffold material within the defect 
over time. However, it should be noted that there was some 
variability observed within scaffolds, due to the different 
sizes of GP particles used to form the 3D scaffolds. This 
limitation can be avoided in future studies through the use 
of a cryo-mill which can generate a more homogeneous GP 
particle size range, which would lead to less variation from 
batch to batch (Almeida et al., 2015). In addition, more 
stringent decellularisation protocols will be developed, 
which will be particularly important when translating this 
scaffold material towards clinical applications (Badylak, 
2004); however, no evidence of a chronic immune response 
was detected at either time point in the scaffold treated 
groups.
Conclusions
This study provides data to support the use of scaffolds 
derived from decellularised growth plate ECM for the 
repair of critically-sized bone defects. MSCs seeded on 
the GP scaffold in vitro underwent robust osteogenesis in 
both chondrogenic and osteogenic culture conditions. Upon 
implantation within a critically-sized cranial defect, the 
acellular GP scaffold facilitated endogenous cell infiltration 
and the deposition of a mineralised de novo bone matrix, 
with significantly more blood vessels and higher levels of 
bone formation compared to the empty controls, illustrating 
the potential of GP ECM as a biomaterial for bone 
regeneration. These scaffolds are relatively easy to produce 
in a process that could be readily scaled up. The fact that 
these scaffolds promote enhanced bone healing without 
the requirement for functionalisation with endogenous 
factors such as BMP-2 points to their potential as a safe and 
cost-effective biomaterial for treating large bone defects.
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Discussion with reviewers
Reviewer 1: Do the authors have an idea which non 
collagneous ECM proteins would be removed by EDTA 
and which would be likely to remain in the demineralised 
scaffold?
Authors: EDTA treatment step is a commonly used de-
calcifying agent, although its complete effects are not easy 
to evaluate. It has been demonstrated that EDTA removes 
calcium phosphate, bone sialoprotein and decorin from 
bone tissue (Gerstenfeld et al., 1994), while others indicate 
that it removes phosphoproteins from teeth in addition 
to calcium and diffusible phosphate (Dimuzio and Veis, 
1978). We have not studied the specific components that 
are being removed from the growth plate tissue, and hope 
to accomplish this in the future with in depth proteomic 
analysis. We believe that the major component removed 
is the mineral phase, but wanted to account for the fact 
that other non-collagenous proteins may also be removed 
during EDTA treatment.
 In our osteogenic culture conditions, all scaffolds tend 
to support robust cell differentiation down an osteogenic 
pathway, with high levels of mineral deposition achieved 
by day 28. Subtle differences are not easily observed using 
these potent osteogenic culture conditions, and as such, 
were not included within this section.
 The EDTA treated scaffold “Demineralised GP” stained 
positively for collagen (Fig. 7); however, we did not do 
immunohistochemistry for specific Col X presence. We 
believe the collagens present to be similar to those observed 
in the non-EDTA treated GP scaffolds, namely Col II and 
Col X.
Reviewer II: The use of rat calvaria defects are 
commonplace for testing bone constructs. However, they 
do not test the effect of mechanical loading on bone healing 
and remodelling. Could the authors discuss their decision 
to use this model with reference to the three Rs?
Authors: Porous scaffold materials such as the ECM 
scaffold, presented in this publication, would be suitable 
for non-load bearing maxillofacial applications, or would 
require the use of a fixation device within a load-bearing 
site. The rat calvarial defect model is widely used for 
testing bone regeneration strategies due to its versatility 
and reproducibility. In our hands, the model also has the 
benefit of minimal morbidity and periprocedural mortality 
rates. They are deemed appropriate analogues to the clinical 
condition they are used to investigate (Spicer et al., 2012).
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Editor’s note: The Scientific Editor responsible for this 
paper was Chris Evans
Fig. 7. Demineralised GP scaffold treated with EDTA 
and cultured in chondrogenic culture conditions for 
28 d stained positively for collagen using picrosirius 
red staining.
